From the beginning, the therapy showed remarkable efficacy in both clinical symptoms and laboratory findings, with an almost complete disappearance of pustulation 48 hours after the first injection. Though 3 to 4 days after each injection, the patient developed minor flares of new pustules, he continuously improved. These small recurrences decreased over time and may be attributed to on-off phenomena of the antibody. In conclusion, the patient showed a rapid response to secukinumab with regard to the cutaneous and systemic manifestations of severe GPP, indicating that this new targeted therapy might also be used to treat PP. Prospective randomized clinical trials are required to further evaluate the efficacy and safety of IL-17 inhibitors for the treatment of GPP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.